US 7,320,991 B2
Analogs of thalidomide as potential angiogenesis inhibitors
William D. Figg, Fairfax, Va. (US); Kurt Eger, Leipzig (Germany); Uwe Teubert, Hameln (Germany); Michael Weiss, Bethesda, Md. (US); Michael Guetschow, Bonn (Germany); Thomas Hecker, Erfurt (Germany); and Sunna Hauschildt, Leipzig (Germany)
Assigned to The United States of America as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health, Washington, D.C. (US)
Appl. No. 10/469,359
PCT Filed Feb. 26, 2002, PCT No. PCT/US02/05868
§ 371(c)(1), (2), (4) Date Nov. 14, 2003,
PCT Pub. No. WO02/068414, PCT Pub. Date Sep. 06, 2002.
Claims priority of provisional application 60/271941, filed on Feb. 27, 2001.
Prior Publication US 2004/0077685 A1, Apr. 22, 2004
Int. Cl. A61K 31/445 (2006.01)
U.S. Cl. 514—323 9 Claims
 
1. A method of inhibiting angiogenesis in a subject having unwanted angiogenesis, comprising:
administering to the subject a therapeutically effective amount of one or more compounds selected from the group consisting of the following compounds, and mixtures thereof or pharmaceutically acceptable salts thereof:

OG Complex Work Unit Drawing
 wherein R4 through R7 are, independently, a halogen, or R5 and R6 are hydrogen and R4 and R7 are methyl groups.